All In Biotech

Drug Trial Radar · NCT02570997

Ascending Dose Study of CT1812 in Healthy Volunteers

A Two-Part, Double-Blind, Placebo-Controlled, Phase I Study of the Safety Pharmacokinetics of Single and Multiple Ascending Doses of CT1812 in Healthy Volunteers

Last checked: Nov 19, 2026Latest source record: Sep 7, 2016 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

80

Actual

Start

Sep 2015

Primary completion

May 2016

Sponsor

Lead sponsor
Cognition TherapeuticsIndustry
Sponsor type
Industry
First posted
Oct 8, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Basic science
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a double-blind, placebo controlled, ascending dose, multi-cohort trial. The study will be conducted in two phases: a single ascending dose (SAD) phase "Part A", followed by a multiple ascending dose (MAD) phase "Part B". In Part A, subjects will receive one dose of study drug. In Part B, subjects within a cohort will receive the same dose daily for 14 days. In both parts, sequential cohorts will be exposed to increasing doses of CT1812 in order to identify the maximum tolerated dose (MTD).

Conditions

  • Cognitive Impairment

Interventions

  • CT1812Drug

    Doses will be escalated in the following sequence: 10mg, 30mg, 90mg, 180mg, 360mg, 650mg.

  • PlaceboDrug

    Matching placebo administered.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence and review of Treatment Emergent Adverse Events [Safety and Tolerability]Time frame: up to 35 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Nucleus Network Limited

    Melbourne, Victoria, Australia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.